52-week follow-up data from type 1 diabetes (“T1D”) patients in COVALENT-112 who completed ≥80% of protocol-specified dosing with the read-out expected in the second quarter of 2026. 26-week primary ...

The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.

The most recent version of NG28, the National Institute for Health and Care Excellence's (NICE) guidelines for managing type 2 diabetes in adults, has been released on February 18, 2026.

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 ...

Diabetes has long been lumped into two categories - Type 1, which often appears in childhood, or Type 2, which is associated with obesity and typically develops later in life. But scientists have ...